Martina Pecoraro: Rome / Italv
Author Block: M. Pecoraro, S. Novelli, E. Messina, L. Laschena, C. Catalano, V. Panebianco; Rome/IT
Purpose: This study aimed to deliver novel, cost-effective, evidence-based, non-invasive predictive risk-adapted diagnostic pathways for faster, earlier, more precise, accessible, and affordable detection and screening of prostate cancer.
Methods or Background: A prospective single-centre cohort study, enrolling patients with PCa suspicion who underwent MRI, MRI- directed fusion biopsy (MRDB), was conducted. Patients also underwent breath analysis using a non-invasive device and molecular analysis (mir-302a-5p and 367). A network-based analysis was used to identify biomarkers drivers of clinically significant PCa.
Results or Findings: Overall, 46 men were enrolled and underwent MR for clinical suspicion of prostate cancer; during the day of the scan or the day of the biopsy procedure, patients also underwent breath analysis and plasma sampling for microRNA expression analysis. A total of 38 patients represented the entire cohort: 12 (31.5%) were negative for PCa, 8 (21.0%) had grade group (GG) 1 PCa, and 18 (47.3%) had GG >1 PCa. The proposed additional non-invasive analysis, including clinical data, MRI biomarkers, breath sensing and microRNAs, provided a higher net benefit with a biopsy avoidance rate of about 23% at a low disease probability.
Conclusion: The integration of multimodal data, including results from medical devices, imaging and omics can further improve the diagnostic pathway of patients with clinical suspicion of prostate cancer.
Limitations: The main limitation is the small sample cohort. Funding for this study: This study was supported by the Italian National Complementary Plan – D3-4-HEALTH project – funded by the Next Generation EU.
Has your study been approved by an ethics committee? Yes
Ethics committee – additional information: No information was provided by submitter.
